Abstract 1888P
Background
The increasing presence of cancer patients in palliative care within emergency departments (ED) worldwide calls for improved care quality. These patients often undergo unnecessary invasive procedures due to challenges in promptly assessing their treatment needs. We developed PalliScore, a rapid assessment tool aimed at helping medical professionals quickly identify palliative care patients in the ED who are less likely to benefit from invasive procedures or ICU admission.
Methods
We retrospectively analyzed data from cancer patients in palliative care admitted to the ED of our hospital in Southeast Brazil, calculating their PalliScore upon admission. This four-step tool incorporates diagnosis of an incurable and life-threatening disease, special care situations (e.g., family or medical team disagreements, uncontrolled symptoms), the “surprise question” (Would you be surprised if this patient died within the next 12 months?), and performance status (ECOG or PPS). Each criterion is scored to reflect the PalliScore, with a threshold of ≥5 suggesting a need to consider limiting invasive interventions after thorough discussion with the patient and healthcare providers.
Results
From March 2021 to July 2023, we assessed 521 patients; 70 (13.68%) received limited intervention care while 449 received intensive care. The average PalliScore was 6.50 for the limited care group and 2.77 for the intensive care group. Statistical analysis using an unpaired t-test showed a significant difference in PalliScore between the groups (odds ratio 3.73, p < 0.0001). Notably, 16.7% of patients with a PalliScore ≥ 5 still received intensive care treatments, whereas 10% of patients with a PalliScore < 5 received limited intervention care.
Conclusions
PalliScore effectively aids ED physicians in making informed decisions regarding invasive procedures and ICU admissions, thereby potentially improving the quality of care for cancer patients in palliative settings. This tool highlights the complex nature of decision-making in palliative care, emphasizing the need for sensitive and individualized patient assessments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1906P - ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy
Presenter: Evert van Aken
Session: Poster session 12
1907P - Deployment of remote patient monitoring in older patients: A real-world experience from 2419 patients across 58 centres in France and Belgium
Presenter: Nicolas Bertrand
Session: Poster session 12
1908P - Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations
Presenter: Panagiotis Filis
Session: Poster session 12
1909TiP - Home-based physical exercise during neoadjuvant treatment for early breast cancer patients (HoPEx-Breast): A pragmatic randomised controlled trial
Presenter: Rita Pichel
Session: Poster session 12
1943P - Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort
Presenter: Julie Deutsch
Session: Poster session 12
1944P - Super-enhancer driven NR3C1 expression promotes 5-FU resistance in gastric cancer
Presenter: Bingya Liu
Session: Poster session 12
Resources:
Abstract
1945P - Stroma-derived bIgH3 (βigH3/TGFBI) is the local mediator of pathological TGFβ activity in pancreatic cancer and a target to treat in patients with high fibrotic activity
Presenter: Morten Karsdal
Session: Poster session 12
1946P - SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via inhibiting cystine transportation in gastric cancer
Presenter: Jianfang Li
Session: Poster session 12
Resources:
Abstract
1947P - Organoid establishment from multiple biological sources in biliopancreatic cancers
Presenter: Michele Zanoni
Session: Poster session 12
1948P - Analysis of cytokines, chemokines, and tumor-infiltrating lymphocytes as immunological markers predicting pathological complete response in triple-negative breast cancer: Exploratory analysis of the NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Poster session 12